Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series

Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erl...

Full description

Bibliographic Details
Main Authors: Paul Zarogoulidis, Aggeliki Rapti, Chrysanthi Sardeli, Panagiotis Chinelis, Anastasia Athanasiadou, Katerina Paraskevaidou, Anastasios Kallianos, Lemonia Veletza, Georgia Trakada, Wolfgang Hohenforst-Schmidt, Haidong Huang
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Respiratory Medicine Case Reports
Subjects:
Gefitinb
Erlotinib and afatinib
Adenocarcinoma
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007117301715

Internet

http://www.sciencedirect.com/science/article/pii/S2213007117301715

Similar Items